Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC

Publisher： John Wiley & Sons Inc

E-ISSN： 1531-4995|125|3|E118-E124

ISSN： 0023-852x

Source： THE LARYNGOSCOPE, Vol.125, Iss.3, 2015-03, pp. : E118-E124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism

By Allensworth Jennifer  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 359-371

Springer Publishing Company

Access to resources Recommend Favorite

SMAC agonists blaze the TRAIL to tumor cells

By MacFarlane M.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 11, 2002-11 ,pp. : 501-502

Elsevier

Access to resources Recommend Favorite

Effects of D-allose in combination with docetaxel in human head and neck cancer cells

By              

International Journal of Oncology, Vol. 45, Iss. 5, 2014-01 ,pp. : 2044-2050

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel combination a gem in NSCLC

By  

Inpharma, Vol. 1, Iss. 1486, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs

By Meldrum B.  

Epilepsy Research, Vol. 50, Iss. 1, 2002-06 ,pp. : 33-40

Elsevier

Access to resources Recommend Favorite